EverSource Wealth Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

EverSource Wealth Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23.7K	Buy	1,015 +28	+3%	+$608	﹤0.01%	2393
2025 Q4	$20.7K	Buy	987 +374	+61%	+$6.53K	﹤0.01%	2360
2025 Q3	$9.43K	Buy	613 +599	+4,279%	+$7.84K	﹤0.01%	2851
2025 Q2	$131	Sell	14 -234	-94%	-$2.58K	﹤0.01%	4097
2025 Q1	$3.05K	Buy	248 +185	+294%	+$2.61K	﹤0.01%	2724
2024 Q4	$833	Buy	+63	New	+$1.08K	﹤0.01%	3027
2023 Q2	–	Sell	-64	Closed	-$1.35K	–	2597
2023 Q1	$1.35K	Buy	+64	New	+$1.59K	﹤0.01%	2046

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

EverSource Wealth Advisors's SNDX Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Syndax Pharmaceuticals (SNDX) stake by 2.8% in Q1 2026, buying an estimated $608 and bringing the position to 1,015 shares worth $23.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2393.

EverSource Wealth Advisors first reported a position in SNDX in Q1 2023 and has held it in 7 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

EverSource Wealth Advisors held 1,015 shares of Syndax Pharmaceuticals worth $23.7K as of Q1 2026.
EverSource Wealth Advisors bought 28 Syndax Pharmaceuticals shares in Q1 2026, an estimated $608.
Syndax Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #2393 holding.
EverSource Wealth Advisors first reported a position in Syndax Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.